ID

30557

Descripción

Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01015248

Link

https://clinicaltrials.gov/show/NCT01015248

Palabras clave

Versiones (1)
  1. 14/6/18 14/6/18 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

14 de junio de 2018

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility MALT LYMPHOMA NCT01015248

Inglés

Eligibility MALT LYMPHOMA NCT01015248

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. histologically proven diagnosis of cd20-positive marginal zone b-cell lymphoma of malt type arisen at any extranodal site (who classification)
Descripción

Marginal Zone B-Cell Lymphoma MALT Lymphoma CD20 antigen positive WHO tumor classification | Origin Site Extranodal

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1367654
UMLS CUI [1,2]
C0242647
UMLS CUI [1,3]
C3888518
UMLS CUI [1,4]
C1301142
UMLS CUI [2,1]
C0439659
UMLS CUI [2,2]
C1515974
UMLS CUI [2,3]
C1517067
2. any stage (ann arbor i-iv)
Descripción

Ann Arbor lymphoma staging system

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0432516
3. the novo disease en any extranodal site. for primary gastric or cutaneous lymphoma, local/specific previous treatment is accepted, just following the below criteria:
Descripción

Disease de novo | Origin Site Extranodal | Prior Therapy Gastric lymphoma | Prior Therapy Cutaneous lymphoma

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C1515568
UMLS CUI [2,1]
C0439659
UMLS CUI [2,2]
C1515974
UMLS CUI [2,3]
C1517067
UMLS CUI [3,1]
C1514463
UMLS CUI [3,2]
C0349532
UMLS CUI [4,1]
C1514463
UMLS CUI [4,2]
C1276146
1. cutaneous lymphoma: recurrent lymphoma after local therapy
Descripción

Cutaneous lymphoma | Recurrent Lymphoma Post Local Therapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1276146
UMLS CUI [2,1]
C4525062
UMLS CUI [2,2]
C0687676
UMLS CUI [2,3]
C1517925
2. gastric lymphoma:
Descripción

Gastric lymphoma

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0349532
b1. h. pylori-negative cases, either de novo (non pre-treated) or at relapse following local therapy (i.e., surgery, radiotherapy or antibiotics).
Descripción

Disease Helicobacter pylori Negative | Disease de novo Untreated | Recurrent disease Post Local Therapy | Operative Surgical Procedures | Therapeutic radiology procedure | Antibiotics

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0079488
UMLS CUI [1,3]
C1513916
UMLS CUI [2,1]
C0012634
UMLS CUI [2,2]
C1515568
UMLS CUI [2,3]
C0332155
UMLS CUI [3,1]
C0277556
UMLS CUI [3,2]
C0687676
UMLS CUI [3,3]
C1517925
UMLS CUI [4]
C0543467
UMLS CUI [5]
C1522449
UMLS CUI [6]
C0003232
b2. h. pylori-positive cases at diagnosis, who failed antibiotic therapy, including patients with: clinical (endoscopic) and histological evidence of disease progression at any time post h. pylori eradication; stable disease with persistent lymphoma at 1 year post h. pylori eradication; relapse (without h. pylori re-infection), after a remission; patients who failed either first line antibiotics or further local treatment (surgery or radiotherapy)
Descripción

Disease Helicobacter pylori Positive | Antibiotics failed | Disease Progression Post Helicobacter eradication therapy | Lymphoma Persistent Post Helicobacter eradication therapy | Recurrent disease Post Remission | Reinfection Helicobacter pylori Absent | First line treatment Antibiotics failed | Local Therapy Additional failed | Operative Surgical Procedures | Therapeutic radiology procedure

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0079488
UMLS CUI [1,3]
C1514241
UMLS CUI [2,1]
C0003232
UMLS CUI [2,2]
C0231175
UMLS CUI [3,1]
C0242656
UMLS CUI [3,2]
C0687676
UMLS CUI [3,3]
C0559761
UMLS CUI [4,1]
C0024299
UMLS CUI [4,2]
C0205322
UMLS CUI [4,3]
C0687676
UMLS CUI [4,4]
C0559761
UMLS CUI [5,1]
C0277556
UMLS CUI [5,2]
C0687676
UMLS CUI [5,3]
C0544452
UMLS CUI [6,1]
C0205339
UMLS CUI [6,2]
C0079488
UMLS CUI [6,3]
C0332197
UMLS CUI [7,1]
C1708063
UMLS CUI [7,2]
C0003232
UMLS CUI [7,3]
C0231175
UMLS CUI [8,1]
C1517925
UMLS CUI [8,2]
C1524062
UMLS CUI [8,3]
C0231175
UMLS CUI [9]
C0543467
UMLS CUI [10]
C1522449
4. no evidence of histologic transformation to a high grade lymphoma
Descripción

Absence Transformation High Grade Lymphoma

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0332197
UMLS CUI [1,2]
C1536010
UMLS CUI [1,3]
C0079740
5. measurable or evaluable disease
Descripción

Measurable Disease | Evaluable Disease

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1513041
UMLS CUI [2]
C1516986
6. age >18 and <85
Descripción

Age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
7. ecog performance status 0-2
Descripción

ECOG performance status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
8. life expectancy of at least 1 year
Descripción

Life Expectancy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023671
9. written informed consent given according to national/local regulations
Descripción

Informed Consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. prior chemotherapy or prior immunotherapy with any anti-cd20 monoclonal antibody
Descripción

Prior Chemotherapy | Prior Immunotherapy | Anti-CD20 Antibody

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1514457
UMLS CUI [2]
C1514461
UMLS CUI [3]
C3891557
2. prior radiotherapy in the last 6 weeks
Descripción

Prior radiation therapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0279134
3. corticosteroids during the last 28 days, unless prednisone chronically administered at a dose <20 mg/day for indications other than lymphoma or lymphoma-related symptoms
Descripción

Adrenal Cortex Hormones | Exception Prednisone U/day chronic | Exclusion Indication Lymphoma | Exclusion Indication Lymphoma Symptoms

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001617
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0032952
UMLS CUI [2,3]
C0456683
UMLS CUI [2,4]
C0205191
UMLS CUI [3,1]
C2828389
UMLS CUI [3,2]
C3146298
UMLS CUI [3,3]
C0024299
UMLS CUI [4,1]
C2828389
UMLS CUI [4,2]
C3146298
UMLS CUI [4,3]
C0024299
UMLS CUI [4,4]
C1457887
4. major impairment of renal function (serum creatinine > 2,5 x upper normal) or liver function (asat/alat <2,5 x upper normal, total bilirubin <2,5x upper normal), unless due to lymphoma involvement.
Descripción

Renal Insufficiency Major | Serum creatinine raised | Liver Dysfunction Major | Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Serum total bilirubin measurement | Exception Etiology Lymphoma

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1565489
UMLS CUI [1,2]
C0205164
UMLS CUI [2]
C0700225
UMLS CUI [3,1]
C0086565
UMLS CUI [3,2]
C0205164
UMLS CUI [4]
C0201899
UMLS CUI [5]
C0201836
UMLS CUI [6]
C1278039
UMLS CUI [7,1]
C1705847
UMLS CUI [7,2]
C0015127
UMLS CUI [7,3]
C0024299
5. impairment of bone marrow function (wbc <3.0x109/l, anc <1.5x109/l, plt <100x109/l), unless due to lymphoma involvement
Descripción

Bone Marrow function Impairment | White Blood Cell Count procedure | Absolute neutrophil count | Platelet Count measurement | Exception Etiology Lymphoma

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0005953
UMLS CUI [1,2]
C0031843
UMLS CUI [1,3]
C0221099
UMLS CUI [2]
C0023508
UMLS CUI [3]
C0948762
UMLS CUI [4]
C0032181
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C0015127
UMLS CUI [5,3]
C0024299
6. evidence of clinically significant cardiac, neurological or metabolic disease, unless due to lymphoma involvement
Descripción

Heart Diseases | Nervous system disorder | Metabolic Diseases | Exception Etiology Lymphoma

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0018799
UMLS CUI [2]
C0027765
UMLS CUI [3]
C0025517
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0015127
UMLS CUI [4,3]
C0024299
7. evidence of symptomatic central nervous system (cns) disease
Descripción

CNS disorder Symptomatic

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0007682
UMLS CUI [1,2]
C0231220
8. active hbv and/or hcv infection
Descripción

Hepatitis B | Hepatitis C

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0019163
UMLS CUI [2]
C0019196
9. known hiv infection
Descripción

HIV Infection

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0019693
10. prior diagnosis of neoplasm within 5 years, except cervical intraepithelial neoplasia type 1 (cin1) or localized non-melanomatous skin cancer
Descripción

Malignant Neoplasms | Exception Cervical Intraepithelial Neoplasia Grade | Exception Skin carcinoma Localized

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0006826
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0206708
UMLS CUI [2,3]
C0441800
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0699893
UMLS CUI [3,3]
C0392752
11. any psychiatric disease potentially hampering compliance with the study protocol and follow-up schedule
Descripción

Mental disorder Interferes with Protocol Compliance

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0004936
UMLS CUI [1,2]
C0521102
UMLS CUI [1,3]
C0525058
12. potential to attend regular visits to the hospital, on an outpatient regimen
Descripción

Hospital visit Regular | Outpatient Regimen

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0545092
UMLS CUI [1,2]
C0205272
UMLS CUI [2,1]
C0029921
UMLS CUI [2,2]
C0040808
13. hypersensibility to any compound of the study medication.
Descripción

Hypersensitivity Investigational New Drugs Compound

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0013230
UMLS CUI [1,3]
C1706082
14. non appropriate contraceptive method in women of childbearing potential or men
Descripción

Childbearing Potential Contraceptive methods Inappropriate | Gender Contraceptive methods Inappropriate

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0700589
UMLS CUI [1,3]
C1548788
UMLS CUI [2,1]
C0079399
UMLS CUI [2,2]
C0700589
UMLS CUI [2,3]
C1548788
15. treatment with any drug under research within 30 days previous to start the study medication.
Descripción

Investigational New Drugs

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0013230
Volver a la parte superior de la página

Similar models

Eligibility MALT LYMPHOMA NCT01015248

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Marginal Zone B-Cell Lymphoma MALT Lymphoma CD20 antigen positive WHO tumor classification | Origin Site Extranodal
Item
1. histologically proven diagnosis of cd20-positive marginal zone b-cell lymphoma of malt type arisen at any extranodal site (who classification)
boolean
C1367654 (UMLS CUI [1,1])
C0242647 (UMLS CUI [1,2])
C3888518 (UMLS CUI [1,3])
C1301142 (UMLS CUI [1,4])
C0439659 (UMLS CUI [2,1])
C1515974 (UMLS CUI [2,2])
C1517067 (UMLS CUI [2,3])
Ann Arbor lymphoma staging system
Item
2. any stage (ann arbor i-iv)
boolean
C0432516 (UMLS CUI [1])
Disease de novo | Origin Site Extranodal | Prior Therapy Gastric lymphoma | Prior Therapy Cutaneous lymphoma
Item
3. the novo disease en any extranodal site. for primary gastric or cutaneous lymphoma, local/specific previous treatment is accepted, just following the below criteria:
boolean
C0012634 (UMLS CUI [1,1])
C1515568 (UMLS CUI [1,2])
C0439659 (UMLS CUI [2,1])
C1515974 (UMLS CUI [2,2])
C1517067 (UMLS CUI [2,3])
C1514463 (UMLS CUI [3,1])
C0349532 (UMLS CUI [3,2])
C1514463 (UMLS CUI [4,1])
C1276146 (UMLS CUI [4,2])
Cutaneous lymphoma | Recurrent Lymphoma Post Local Therapy
Item
1. cutaneous lymphoma: recurrent lymphoma after local therapy
boolean
C1276146 (UMLS CUI [1])
C4525062 (UMLS CUI [2,1])
C0687676 (UMLS CUI [2,2])
C1517925 (UMLS CUI [2,3])
Gastric lymphoma
Item
2. gastric lymphoma:
boolean
C0349532 (UMLS CUI [1])
Disease Helicobacter pylori Negative | Disease de novo Untreated | Recurrent disease Post Local Therapy | Operative Surgical Procedures | Therapeutic radiology procedure | Antibiotics
Item
b1. h. pylori-negative cases, either de novo (non pre-treated) or at relapse following local therapy (i.e., surgery, radiotherapy or antibiotics).
boolean
C0012634 (UMLS CUI [1,1])
C0079488 (UMLS CUI [1,2])
C1513916 (UMLS CUI [1,3])
C0012634 (UMLS CUI [2,1])
C1515568 (UMLS CUI [2,2])
C0332155 (UMLS CUI [2,3])
C0277556 (UMLS CUI [3,1])
C0687676 (UMLS CUI [3,2])
C1517925 (UMLS CUI [3,3])
C0543467 (UMLS CUI [4])
C1522449 (UMLS CUI [5])
C0003232 (UMLS CUI [6])
Disease Helicobacter pylori Positive | Antibiotics failed | Disease Progression Post Helicobacter eradication therapy | Lymphoma Persistent Post Helicobacter eradication therapy | Recurrent disease Post Remission | Reinfection Helicobacter pylori Absent | First line treatment Antibiotics failed | Local Therapy Additional failed | Operative Surgical Procedures | Therapeutic radiology procedure
Item
b2. h. pylori-positive cases at diagnosis, who failed antibiotic therapy, including patients with: clinical (endoscopic) and histological evidence of disease progression at any time post h. pylori eradication; stable disease with persistent lymphoma at 1 year post h. pylori eradication; relapse (without h. pylori re-infection), after a remission; patients who failed either first line antibiotics or further local treatment (surgery or radiotherapy)
boolean
C0012634 (UMLS CUI [1,1])
C0079488 (UMLS CUI [1,2])
C1514241 (UMLS CUI [1,3])
C0003232 (UMLS CUI [2,1])
C0231175 (UMLS CUI [2,2])
C0242656 (UMLS CUI [3,1])
C0687676 (UMLS CUI [3,2])
C0559761 (UMLS CUI [3,3])
C0024299 (UMLS CUI [4,1])
C0205322 (UMLS CUI [4,2])
C0687676 (UMLS CUI [4,3])
C0559761 (UMLS CUI [4,4])
C0277556 (UMLS CUI [5,1])
C0687676 (UMLS CUI [5,2])
C0544452 (UMLS CUI [5,3])
C0205339 (UMLS CUI [6,1])
C0079488 (UMLS CUI [6,2])
C0332197 (UMLS CUI [6,3])
C1708063 (UMLS CUI [7,1])
C0003232 (UMLS CUI [7,2])
C0231175 (UMLS CUI [7,3])
C1517925 (UMLS CUI [8,1])
C1524062 (UMLS CUI [8,2])
C0231175 (UMLS CUI [8,3])
C0543467 (UMLS CUI [9])
C1522449 (UMLS CUI [10])
Absence Transformation High Grade Lymphoma
Item
4. no evidence of histologic transformation to a high grade lymphoma
boolean
C0332197 (UMLS CUI [1,1])
C1536010 (UMLS CUI [1,2])
C0079740 (UMLS CUI [1,3])
Measurable Disease | Evaluable Disease
Item
5. measurable or evaluable disease
boolean
C1513041 (UMLS CUI [1])
C1516986 (UMLS CUI [2])
Age
Item
6. age >18 and <85
boolean
C0001779 (UMLS CUI [1])
ECOG performance status
Item
7. ecog performance status 0-2
boolean
C1520224 (UMLS CUI [1])
Life Expectancy
Item
8. life expectancy of at least 1 year
boolean
C0023671 (UMLS CUI [1])
Informed Consent
Item
9. written informed consent given according to national/local regulations
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Prior Chemotherapy | Prior Immunotherapy | Anti-CD20 Antibody
Item
1. prior chemotherapy or prior immunotherapy with any anti-cd20 monoclonal antibody
boolean
C1514457 (UMLS CUI [1])
C1514461 (UMLS CUI [2])
C3891557 (UMLS CUI [3])
Prior radiation therapy
Item
2. prior radiotherapy in the last 6 weeks
boolean
C0279134 (UMLS CUI [1])
Adrenal Cortex Hormones | Exception Prednisone U/day chronic | Exclusion Indication Lymphoma | Exclusion Indication Lymphoma Symptoms
Item
3. corticosteroids during the last 28 days, unless prednisone chronically administered at a dose <20 mg/day for indications other than lymphoma or lymphoma-related symptoms
boolean
C0001617 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0032952 (UMLS CUI [2,2])
C0456683 (UMLS CUI [2,3])
C0205191 (UMLS CUI [2,4])
C2828389 (UMLS CUI [3,1])
C3146298 (UMLS CUI [3,2])
C0024299 (UMLS CUI [3,3])
C2828389 (UMLS CUI [4,1])
C3146298 (UMLS CUI [4,2])
C0024299 (UMLS CUI [4,3])
C1457887 (UMLS CUI [4,4])
Renal Insufficiency Major | Serum creatinine raised | Liver Dysfunction Major | Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Serum total bilirubin measurement | Exception Etiology Lymphoma
Item
4. major impairment of renal function (serum creatinine > 2,5 x upper normal) or liver function (asat/alat <2,5 x upper normal, total bilirubin <2,5x upper normal), unless due to lymphoma involvement.
boolean
C1565489 (UMLS CUI [1,1])
C0205164 (UMLS CUI [1,2])
C0700225 (UMLS CUI [2])
C0086565 (UMLS CUI [3,1])
C0205164 (UMLS CUI [3,2])
C0201899 (UMLS CUI [4])
C0201836 (UMLS CUI [5])
C1278039 (UMLS CUI [6])
C1705847 (UMLS CUI [7,1])
C0015127 (UMLS CUI [7,2])
C0024299 (UMLS CUI [7,3])
Bone Marrow function Impairment | White Blood Cell Count procedure | Absolute neutrophil count | Platelet Count measurement | Exception Etiology Lymphoma
Item
5. impairment of bone marrow function (wbc <3.0x109/l, anc <1.5x109/l, plt <100x109/l), unless due to lymphoma involvement
boolean
C0005953 (UMLS CUI [1,1])
C0031843 (UMLS CUI [1,2])
C0221099 (UMLS CUI [1,3])
C0023508 (UMLS CUI [2])
C0948762 (UMLS CUI [3])
C0032181 (UMLS CUI [4])
C1705847 (UMLS CUI [5,1])
C0015127 (UMLS CUI [5,2])
C0024299 (UMLS CUI [5,3])
Heart Diseases | Nervous system disorder | Metabolic Diseases | Exception Etiology Lymphoma
Item
6. evidence of clinically significant cardiac, neurological or metabolic disease, unless due to lymphoma involvement
boolean
C0018799 (UMLS CUI [1])
C0027765 (UMLS CUI [2])
C0025517 (UMLS CUI [3])
C1705847 (UMLS CUI [4,1])
C0015127 (UMLS CUI [4,2])
C0024299 (UMLS CUI [4,3])
CNS disorder Symptomatic
Item
7. evidence of symptomatic central nervous system (cns) disease
boolean
C0007682 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
Hepatitis B | Hepatitis C
Item
8. active hbv and/or hcv infection
boolean
C0019163 (UMLS CUI [1])
C0019196 (UMLS CUI [2])
HIV Infection
Item
9. known hiv infection
boolean
C0019693 (UMLS CUI [1])
Malignant Neoplasms | Exception Cervical Intraepithelial Neoplasia Grade | Exception Skin carcinoma Localized
Item
10. prior diagnosis of neoplasm within 5 years, except cervical intraepithelial neoplasia type 1 (cin1) or localized non-melanomatous skin cancer
boolean
C0006826 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0206708 (UMLS CUI [2,2])
C0441800 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0699893 (UMLS CUI [3,2])
C0392752 (UMLS CUI [3,3])
Mental disorder Interferes with Protocol Compliance
Item
11. any psychiatric disease potentially hampering compliance with the study protocol and follow-up schedule
boolean
C0004936 (UMLS CUI [1,1])
C0521102 (UMLS CUI [1,2])
C0525058 (UMLS CUI [1,3])
Hospital visit Regular | Outpatient Regimen
Item
12. potential to attend regular visits to the hospital, on an outpatient regimen
boolean
C0545092 (UMLS CUI [1,1])
C0205272 (UMLS CUI [1,2])
C0029921 (UMLS CUI [2,1])
C0040808 (UMLS CUI [2,2])
Hypersensitivity Investigational New Drugs Compound
Item
13. hypersensibility to any compound of the study medication.
boolean
C0020517 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C1706082 (UMLS CUI [1,3])
Childbearing Potential Contraceptive methods Inappropriate | Gender Contraceptive methods Inappropriate
Item
14. non appropriate contraceptive method in women of childbearing potential or men
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C1548788 (UMLS CUI [1,3])
C0079399 (UMLS CUI [2,1])
C0700589 (UMLS CUI [2,2])
C1548788 (UMLS CUI [2,3])
Investigational New Drugs
Item
15. treatment with any drug under research within 30 days previous to start the study medication.
boolean
C0013230 (UMLS CUI [1])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial